Background: Endometrial carcinoma often arises from normal endometrial glandular cells
Introduction
Uterine endometrial carcinoma is one of the most common malignancies in the female genital tract (1), accounting for approximately 25% of all deaths ascribed to cancer of the female genital tract in developed countries (2) . The number of patients with this tumor has been increasing rapidly in Japan (3) . Thus, further understanding of this malignancy in terms of the carcinogenetic process and biological characteristics is important for better management of this disease.
Endometrial carcinoma is clinicopathologically classified into two conceptional subgroups; type 1 and type 2 (1) . The type 1 tumor is dominant, making up approximately 80% of all cases, and thought to arise from normal endometrial glandular cells via a precursor, atypical endometrial hyperplasia. Previous papers have reported the accumulation of genetic abnormalities, such as mutations of the PTEN, K-Ras, and p53 genes and microsatellite instability, to be involved in this tumorigenetic cascade (4) . However, the percentage of endometrial carcinomas in which such genetic abnormalities have been identified is reportedly 50-60%, therefore, the involvement of other unknown genetic abnormalities has been presumed.
Difficulty in the detection of genetic abnormalities in endometrial carcinogenesis, especially those involved in the early stages of the hyperplasia-carcinoma sequence, is partly attributed to the histological structure of the normal endometrium. Normal endometrial glandular cells, from which endometrial carcinomas develop, are surrounded by ample stromal cells. The early step of neoplastic change is believed to occur in limited loci in endometrial glands as observed in endometrial hyperplasia. Therefore, if DNA is extracted from a tissue block, subtle changes may be missed due to the intermingling of the intervening stroma and normal glands. In this regard, the precise collection of tissue samples from neoplastic glands is mandatory to analyze the early and subtle genetic changes. To solve this problem, we employed the laser captured microdissection (LCM) technique, which enabled us to obtain histologically specific cells under microscopic observation (5) . Using this technique, we exclusively collected normal endometrial glandular cells, hyperplastic cells and carcinoma cells from tissue sections of the same patients to abrogate the effect of gene polymorphism. In addition, to detect the genes responsible for the neoplastic process, differences in gene expression among the three cell types were investigated using a microarray. Accordingly, a group of genes whose expression was up-regulated stepwise as the disease progressed was identified. Among them, we focused on lipocalin2 (LCN2), because it had the largest magnitude of up-regulation in the neoplastic tissues. Lipocalin2, a small protein of 25kD, reportedly functions as a mediator of inflammation and iron ion transport (6~8). In this study, we examined the expression and possible functions of lipocalin2 in endometrial tissues.
Materials & Methods

Fresh tissue samples and laser-captured microdissection (LCM)
Immediately after the uterus was removed, fresh tissue of normal and neoplastic parts of approximately one hundred endometrial carcinomas was extirpated. The normal part was obtained from a macroscopically "flat" area with underlying myometrium and neoplastic part was mainly from the border of the tumor. These tissues were embedded in OCT compound, and flash frozen and stored at -80 o C prior to use. The histological diagnosis of these samples was made using hematoxylin and eosin (H &E)-stained frozen sections. Regarding the diagnostic criteria, endometrial hyperplasia was defined by marked glandular crowding (back to back structure) with cellular atypia such as round and enlarged nucleus, granular chromatin pattern and nucleoli. Endometrial carcinoma was defined by apparent stromal invasion as shown by multiple cribriform patterns. Cases lacking these findings were excluded.
Consequently, three cases that simultaneously contained normal proliferative, hyperplastic and cancerous areas were identified. All three carcinomas were endometrioid adenocarcinoma, grade 1. Likewise, there were only 3 cases that included normal proliferative and hyperplastic sites in the same patient. From these 6 cases, ten to thirty serial sections (10μm-thick for LCM, 5μm-thick for H & E) of each frozen tissue sample were cut using a Cryostat (Sakura Seiki, Tokyo, Japan), fixed in 70% ethanol. One of 5 sections was stained with H&E for reference, and the remainders were stained hematoxylin and used for LCM. Normal, hyperplastic and malignant glands were precisely collected using LCM (LM100, Olympus, Tokyo, Japan). At least 20,000 laser shots were performed to obtain the respective target tissue sample. Each fresh tissue sample was used with the approval of the Ethics Committee of Shinshu University, after obtaining written consent from the patients.
Microarray analysis
Total RNA was extracted from the tissues obtained by LCM, using an RNeasy Micro Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions, and then a quality of it was checked. The total RNA was then subjected to two rounds of T7-based aRNA amplification and aminoallyle labeling using an Amino Allyl MessageAmp aRNA Kit (Ambion, Austin, TX) according to the instructions. The amplified RNA (aRNA) was coupled with Cye-Dye. Cy5-coupled aRNA of neoplastic cells and cy3-coupled aRNA of normal glandular cells of the same patients were mixed and hybridized with AceGene Human oligo chip array 30k, subset A (Hitachi software, Tokyo, Japan) , containing 10,368 probe sets for 9881 genes, according to the instructions. The hybridized arrays were scanned using a Packard GSI Lumonics Scan Array 4000 (PerkinElmer, Boston, MA) and the results were quantitatively analyzed using QuantArray software (GSI Lumonics, Unterschleissheim, Germany). Data from each microarray were normalized using LOWESS normalization. We selected genes which were expressed greater than 1.5-fold or less than 0.67-fold in neoplastic tissues compared with corresponding normal tissues.
Validation of gene expression using real time-quantitative PCR
Fresh frozen tissues from four samples each of normal proliferative endometrial glands, atypical endometrial hyperplasia and grade 1 endometrial carcinoma were subjected to analysis. Total RNA was extracted from the tissues using LCM and an RNeasy Micro Kit and treated with DNase I. cDNA was synthesized from each total RNA sample using PrimeScript RT reagent (Takara Bio Inc. Otsu, Japan). Reactions were carried out with the SYBR Green method. A SYBR Green PCR master mix (Takara Bio Inc.) was used in 20-μl reaction mixtures set up in triplicate with each primer. Reactions were run at 95°C for 10 seconds followed by 45 cycles of 95 °C for 3 seconds and 62 °C for 25 seconds. A dissociation curve was then used to ensure that the fluorescence signal was not derived from the formation of primer-dimer. The threshold number of cycles was determined. Gene expression was quantified by the comparative Ct method using β-actin (ACTB) as the internal control. Primer sets used for real time RT-PCR are summarized in Table 1 Indirect immunohistochemical staining was performed using a goat-polyclonal anti-LCN2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and Histofine SAB-PO detector kit (Nichirei, Tokyo, Japan) with microwave pretreatment as described previously (9). Granulocytes in the same tissue section were used as a positive control. 
Immunofluorescent staining
Immunofluorescent staining for cultured cells was performed as described previously (10), using a goat polyclonal anti-lipocalin2 antibody (x 50) and a Fluorescein Isothiocyanate (FITC)-conjugated anti-goat IgG antibody (x 100, green, Sigma-Aldrich, Saint Louis, MO).
Cell culture and transfection
The endometrial carcinoma cell lines Ishikawa, and HEC1A and HEC1B were gifts from Dr.
H. Nishida (Kasumigaura Medical Center, Tsuchiura, Japan) and Dr. H. Kuramoto at Kitazato University (Sagamihara, Japan), respectively. HHUA was purchased from the Riken Cell Bank (Saitama, Japan) with the permission of Dr. Ishiwata at the Ishiwata Laboratory (Mito, Japan). KLE and RL95-2 were purchased from American Type Culture Collection (Rockville, MD). Ishikawa and HHUA were derived from well differentiated endometrial adenocarcinoma. HEC1A and HEC1B were from moderately differentiated endometrial adenocarcinoma. RL95-2 and KLE were from moderately differentiated adenosquamous carcinoma and poorly differentiated endometrial carcinoma, respectively. Primary cultures of normal proliferative phase endometrial glandular cells were prepared from the surgically resected endometrial tissues according to a previous study (9) with written consent from the patients. The human LCN2 expression vector, pCEP4-LCN2, was kindly provided by Dr.
Kornelia Polyak (11).
To establish endometrial carcinoma cells that stably express lipocalin2, Ishikawa and HEC1B cells were transfected with pCEP4-LCN2 or pCEP4 alone by lipofection according to the supplier's instructions (Lipofectamine 2000, Invitrogen, Carlsbad, CA). At 48 hours after transfection, the medium was changed to selection medium and a stable expression clone was selected.
Western blot analysis
Proteins extracted from sub-confluent cultures of endometrial carcinoma cells (Ishikawa, HHUA, HEC1A, HEC1B, KLE) and cultured normal endometrial glandular cells were subjected to a Western blot analysis as described previously (9) using goat-polyclonal anti-LCN2 antibody for primary antibody. Proteins of cytoplasmic and nuclear fractions were extracted using a NE-PER nuclear and cytoplasmic extraction Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. Blocking was performed with 5% nonfat milk or 3% bovine serum albmin in PBS-T for 1 hour at room temperature. The membranes were blotted with primary antibody at 4 o C overnight and then incubated with a peroxidase-conjugated secondary antibody. Bound antibodies were visualized using the ECL western blot detection reagent (Amersham, Piscataway, NJ). To confirm the results obtained using goat-polyclonal anti-LCN2 antibody, the expression of lipocalin2 protein was re-examined using rat-monoclonal anti-human lipocalin2 antibody in Ishikawa cells.
RT-PCR
Endometrial carcinoma cell lines (Ishikawa, HHUA, HEC1A, HEC1B, KLE) and cultured normal proliferative phase endometrial glands were subjected to RT-PCR. Total RNA extracted by TRIzol reagent (Invitrogen) according to the manufacturer's instructions and primers for lipocalin2 and β-actin (Table 1) were used for RT-PCR. In brief, 1μg of total RNA was treated with 1 U/10 µl DNase I (Life Technologies, Gaithersburg, MD). RT was performed using an RNA PCR Kit (Takara Bio Inc.). The corresponding cDNA fragments were denatured at 94°C for 3 minutes, then subjected to 28 cycles of denaturing at 94 °C for 10 seconds, annealing at 58°C for 10 seconds and extension at 72°C for 20 seconds for lipocalin2, and 24cycles for β-actin.
Effect of the inhibition of methylation on the expression of lipocalin2
Endometrial carcinoma HHUA, Ishikawa, HEC1A, HEC1B, KLE and RL-95-2 cells were treated with a methylation inhibitor, 5-azacytidine (5-aza-C, Sigma-Aldrich), at 5μM for 72
hours. Cells were harvested and RNA was extracted using TRIzol agent. The expression of lipocalin2 mRNA was evaluated using a semi-quantitative RT-PCR.
WST-1 assay
Ishikawa and HEC1B cells transfected with pCEP4-LCN2 or pCEP4 alone were plated at a density of 2.0 x 10 3 cells into 96-well plates and cultured under optimal conditions (37 o C in a 5% CO 2 incubator) for measurement. The cell viability was measured by a modified A 450 was measured using a microplate reader (Multiskan JX, Thermo Fisher Scientific).
Matrigel invasion assay
Matrigel invasion was performed according to a previous study (12). In brief, polycarbonate 
Results
According to the laser captured microdissection-microarray analysis, a total of 51 genes were up-regulated, and 23 genes were down-regulated in hyperplastic and cancerous endometrial epithelia compared with normal glandular cells (Fig. 1 ). Among them, 25 genes were selected according to the possible oncogenetic characteristics on the basis of GenBank data (http://www.ncbi.nlm.nih.gov/Genbank/), and subjected to real-time RT-PCR to quantitatively ascertain the level of their expression. Accordingly, we selected nine up-regulated genes and one down-regulated gene (Fig. 2 ) that were expressed greater than 2-fold or less than 0.5-fold in more than three-fourth cases of hyperplasia and/or carcinoma compared with normal endometria. Of the nine up-regulated genes, lipocalin2 (LCN2) was eventually selected for further analysis, because it showed the largest magnitude of amplification in carcinoma tissues compared to normal and hyperplastic endometria.
Immunohistochemical expression of lipocalin2 protein
Immunoreactivity for lipocalin2 protein using goat polyclonal antibody in formalin-fixed, paraffin-embedded sections was observed both in the cytoplasm and in the nucleus (Figs.
3a-e). Because the nuclear staining of lipocalin2 has not been reported, immunohistochemical expression of lipocalin2 was re-examined using another antibody; rat-monoclonal anti-human lipocalin2 antibody. The result also indicated the similar cytoplasmic and nuclear staining (Fig. 3f) .
The positivity index (PI) for cytoplasmic lipocalin2 in normal endometrial glands in the proliferative and secretory phases was 1.6 ± 2.1 and 1.6 ± 2.5 (mean ± standard deviation, SD), respectively (Fig. 3g) . The cytoplasmic PI of lipocalin2 increased in a stepwise manner, and the PI of atypical endometrial hyperplasia and endometrial carcinoma was 4.7 ± 4.7 and 10.3 ± 14.1, respectively. The cytoplasmic PI of lipocalin2 in carcinoma was significantly higher than that in the proliferative phase (p=0.020, Fig. 3g ). There were a few cells with nuclear staining in normal endometrium and hyperplasia, whereas clear nuclear staining was observed in 22 cases of endometrial carcinoma (Fig. 3e) . The cytoplasmic PI of grade 2 tumors was significantly greater than that of grade 1(p=0.009, Fig. 3 h) . The nuclear PI of grade 3 tumors and stage III-IV tumors were significantly greater than that of grade 1 (p=0.048) and stage I-II (p=0.002), respectively (Fig. 3h) . Regarding the prognostic value of lipocalin2, endometrial carcinoma patients with elevated level of lipocalin2 protein (PI in the cytoplasm≧10, 47/131) had significantly shorter survival periods (p=0.012, Fig. 4a ).
Likewise, elevated nuclear staining (PI in the nucleus≧10, 22/131 ) was associated with the poor survival (p<0.0005, Fig. 4b ). In stage III-IV patients, the survival of those with elevated cytoplasmic lipocalin2 expression was shorter than that with non-elevated lipocalin2, but the difference was not significant (p=0.108, Fig. 4c) . However, the survival of patients with nuclear expression of lipocalin2 was significantly shorter than that with weak or no expression of lipocalin2 (p=0.003, Fig. 4d ).
Expression of lipocalin2 in endometrial carcinoma cells
The expression of lipocalin2 protein and mRNA was examined in five endometrial carcinoma HEC1B and KLE cells (Fig. 5a ).
Subcellular localization of lipocalin2 protein
Because immunostaining for lipocalin2 in endometrial carcinoma showed both cytoplasmic and nuclear staining, we investigated the subcellular localization of lipocalin2 using endometrial carcinoma cell lines. The expression of lipocalin2 protein recognized by goat-polyclonal anti-LCN2 antibody was ascertained both in the cytoplasmic and in the nuclear fraction of HHUA and Ishikawa cells (Fig. 5b) . Nuclear and cytoplasmic expression of lipocalin2 in Ishikawa cells was also detected by rat-monoclonal anti-human lipocalin2
antibody (data not shown). Immunolabeling of lipocalin2 in HHUA cells also showed both nuclear and cytoplasmic staining (Fig. 5c ).
Lipocalin2 expression and lipocalin2 gene methylation
Because the expression of lipocalin2 in pancreatic carcinoma was reportedly enhanced by hypomethylation of the lipocalin2 gene promoter (14), we examined the effect of DNA methylation on the expression of lipocalin2 using a de-methylating agent, 5-aza-C. The results indicated that the expression of lipocalin2 in HEC1A, HEC1B and KLE cells, which
showed relatively weak expression of lipocalin2 mRNA before the treatment by 5-aza-C, increased after the treatment (Fig. 5d) .
Effect of lipocalin2 on cell proliferation and invasion
We then examined the effect of lipocalin2 on cell proliferation and invasion using endometrial carcinoma Ishikawa and HEC1B cells. Transfection with a lipocalin2-expressing vector, pCEP4-LCN2, was confirmed to increase the expression of lipocalin2 mRNA. The WST-1 assay revealed that the forced expression of lipocalin2 significantly increased cell viability of HEC1B cells by 371 % (p=0.0001), and that of Ishikawa cells by 27 % (Fig. 6a,   b ). The contribution of lipocalin2 to invasive potential was also examined using the Matrigel invasion assay. The results indicated that transfection of the lipocalin2 gene increased the number of invading cells by 89 % (p=0.0002) and by 645% (p<0.0001) in Ishikawa cells and HEC1B cells, respectively (Fig. 6c) .
Discussion
The method of laser captured microdissection (LCM) used in the present study makes it possible to obtain highly specific cells from thin-sliced tissue sections. Therefore, the technique is suitable for collecting small samples of a target tissue, and this advantage is enhanced when the target sites is surrounded by stromal cells such as the endometrium. With the present microarray system, at least 5μg of aminoallyl antisense RNA is required according to the manufacturer. However, the LCM retrieved only 100-500ng of total RNA even when we punched out more than 20,000 laser shots in one tissue sample. Therefore, we were obliged to perform two rounds of preparatory T7-RNA polymerase amplification for the microarray analysis. The first round yielded about 1μg of aRNA, while the second amplification generated more than 50 μg, enough for a microarray analysis. However, the possibility that long genes might have been lost during the two rounds of amplification must be taken into account. Also, there is a possibility that genetic changes such as point mutations in exons cannot be detected. However, when the transcription of a gene is regulated by a point mutation of the promoter sequence, detection is theoretically possible by detecting changes in the transcription of downstream genes. In the present study, we eventually focused on lipocalin2, because the increase in the expression of lipocalin2 during endometrial carcinogenesis was the largest observed. can be controlled in an autocrine/paracrine mechanism, because a recent study identified the lipocalin2 receptor (29) .
In conclusion, we identified lipocalin2 using a LCM-microarray technique as a protein whose expression was up-regulated during tumorigenetic and developmental processes of endometrial carcinoma. Experiments in vitro revealed that the expression of lipocalin2 affected the growth and invasive potential of endometrial carcinoma cells.
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